Pharmacological treatment of the maintenance phase of bipolar depression: focus on relapse prevention studies and the impact of design on generalizability

  • Keming Gao
  • David E. Kemp
  • Joseph R. Calabrese
Part of the Milestones in Drug Therapy book series (MDT)


The goal of pharmacological treatment of bipolar disorder is to prevent future occurrences of mood episodes. To achieve this goal, medications must demonstrate efficacy in the prevention of both manic/hypomanic and depressive relapses/recurrences. Currently, the efficacy of most pharmacological agents in the maintenance treatment of bipolar disorder has been studied using relapse prevention designs, in which only patients who tolerate and respond to a studied drug(s) in the acute phase (mania or depression) can enter the maintenance phase. Subsequently, the results from relapse prevention studies are not generalizable, not only because of the design, but also because of different index mood episodes. So far, however, only lithium and lamotrigine, and to some extent divalproex, have been investigated in both manic and depressive index episodes, while olanzapine and aripiprazole have been evaluated in manic index episodes. To facilitate the application of currently available data, this chapter will systematically examine randomized, blinded, controlled maintenance studies enrolling ≥100 patients and lasting ≥6 months.


Bipolar Disorder Maintenance Phase Relapse Prevention Bipolar Depression Young Mania Rate Scale 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB (2002) The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59: 530–537PubMedCrossRefGoogle Scholar
  2. 2.
    Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, Solomon DA, Leon AC, Keller MB (2003) A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 60: 261–269PubMedCrossRefGoogle Scholar
  3. 3.
    Calabrese JR, Hirschfeld RMA, Frye MA, Reed ML (2004) Impact of depressive symptoms compared with manic symptoms in bipolar disorder: Results of a U.S. community-based sample. J Clin Psychiatry 65: 1499–1504PubMedGoogle Scholar
  4. 4.
    MacQueen GM, Young LT, Joffe RT (2001) A review of psychosocial outcome in patients with bipolar disorder. Acta Psychiatr Scand 103: 163–170PubMedCrossRefGoogle Scholar
  5. 5.
    MacQueen GM, Young LT, Robb JC, Marriott M, Cooke RG, Joffe RT (2000) Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatr Scand 101: 374–381PubMedCrossRefGoogle Scholar
  6. 6.
    Goodwin F, Jamison K (eds): (2007) Manic-depressive illness: bipolar disorder and recurrent depression, 2nd edition. Oxford University Press, New YorkGoogle Scholar
  7. 7.
    Isometsä ET, Henriksson MM, Aro HM, Lünnqvist JK (1994) Suicide in bipolar disorder in Finland. Am J Psychiatry 151: 1020–1024PubMedGoogle Scholar
  8. 8.
    Dilsaver SC, Chen YW, Swann AC, Shoaib AM, Tsai-Dilsaver Y, Krajewski KJ (1997) Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psychiatry Res 73: 47–56PubMedCrossRefGoogle Scholar
  9. 9.
    Calabrese JR, Goldberg JF, Ketter TA, Suppes T, Frye M,White R, DeVeaugh-Geiss A, Thompson TR (2006) Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two doubleblind maintenance studies. Biol Psychiatry 59: 1061–1064PubMedCrossRefGoogle Scholar
  10. 10.
    Shapiro DR, Quitkin FM, Fleiss JL (1989) Response to maintenance therapy in bipolar illness. Effect of index episode. Arch Gen Psychiatry 46: 401–405PubMedGoogle Scholar
  11. 11.
    Calabrese JR, Rapport DJ, Shelton MD, Kimmel SE (2001) Evolving methodologies in bipolar disorder maintenance research. Br J Psychiatry 178 (Suppl 41): S157–163CrossRefGoogle Scholar
  12. 12.
    Prien RF, Klett CJ, Caffey EM Jr (1973) Lithium carbonate and imipramine in prevention of affective episodes: A comparison in recurrent affective illness. Arch Gen Psychiatry 29: 420–425PubMedGoogle Scholar
  13. 13.
    Prien RF, Caffey EM Jr, Klett CJ (1973) Prophylactic efficacy of lithium carbonate in manicdepressive illness. Arch Gen Psychiatry 28: 334–337Google Scholar
  14. 14.
    Prien RF, Klett CJ, Caffey EM Jr (1974) Lithium prophylaxis in recurrent affective illness. Am J Psychiatry 131: 198–203PubMedGoogle Scholar
  15. 15.
    Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, Johnson WE (1984) Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 41: 1096–1104PubMedGoogle Scholar
  16. 16.
    Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N et al (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64: 1013–1024PubMedCrossRefGoogle Scholar
  17. 17.
    Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60: 392–400PubMedCrossRefGoogle Scholar
  18. 18.
    Calabrese JR, Shelton MD, Rapport DJ,Youngstrom EA, Jackson K, Bilali S, Ganocy SJ, Findling RL (2005) A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapidcycling bipolar disorder. Am J Psychiatry 162: 2152–2161PubMedCrossRefGoogle Scholar
  19. 19.
    Keck PE, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, Carlson BX, Marcus RN, Sanchez R; for the Aripiprazole Study Group (2007) Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 68: 1480–1491PubMedCrossRefGoogle Scholar
  20. 20.
    Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW et al (2005) Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 162: 1281–1290PubMedCrossRefGoogle Scholar
  21. 21.
    Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL (2006) Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 163: 247–256PubMedCrossRefGoogle Scholar
  22. 22.
    Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD et al (2004) Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer v. mood stabilizer alone. Br J Psychiatry 184: 337–345PubMedCrossRefGoogle Scholar
  23. 23.
    Bowden CL, Calabrese JR, McElroy SL, Gyulai L,Wassef A, Petty F, Pope HG Jr, Chou JC, Keck PE Jr, Rhodes LJ et al (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 57: 481–489PubMedCrossRefGoogle Scholar
  24. 24.
    Calabrese JR, Vieta E, El-Mallakh R, Findling RL,Youngstrom EA, Elhaj O (2004) Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 56: 957–963PubMedCrossRefGoogle Scholar
  25. 25.
    Ghaemi SN, Pardo RR, Hsu DJ (2004) Strategies for preventing the recurrence of bipolar disorder. J Clin Psychiatry 65 (Suppl 10): 16–23PubMedGoogle Scholar
  26. 26.
    Gyulai L, Bowden CL, McElroy SL, Calabrese JR, Petty F, Swann AC, Chou JC, Wassef A, Risch CS, Hirschfeld RM et al (2003) Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28: 1374–1382PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2009

Authors and Affiliations

  • Keming Gao
    • 1
  • David E. Kemp
    • 1
  • Joseph R. Calabrese
    • 1
  1. 1.Department of Psychiatry, Bipolar Disorder Research Center in Mood Disorders ProgramUniversity Hospitals Case Medical Center, Case Western Reserve University School of MedicineClevelandUSA

Personalised recommendations